Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)
NCT00439192 is registered in ClinicalTrials.gov with elbion AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)
- Lead sponsor
- elbion AG
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 28, 2007
- Completion date
- August 31, 2007
- Enrollment
- 275 (estimated)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.
overactive bladder, urinary incontinence